79 results about "Core protein" patented technology

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The invention discloses a viral ARDS prognosis evaluation system based on protein joint detection, and the system comprises a sample processing module which is used for carrying out serum standardization pretreatment; the protein detection module is used for performing iBAQ quantification of IL6ST / FOXO3 / TLR7 based on DIA mass spectrometry, defining a targeted therapy threshold value and realizing targeted quantification of the core protein; and the intelligent analysis module is used for realizing cross-age risk layering based on a multivariable logic regression model. B cell function states are reflected by combining serum IL6ST / FOXO3 / TLR7 protein expression levels, a multivariable logistic regression model is constructed, and unified risk stratification of patients of all ages from children to the elderly is achieved; by locking an IL6ST / FOXO3 / TLR7 pathway, a targeted therapy threshold is defined to directly guide targeted therapy, and immune intervention is facilitated.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention discloses a gastric cancer biomarker composition as well as a screening method and application thereof, and belongs to the technical field of bioinformatics. The screening method of the gastric cancer biomarker composition comprises the following steps: firstly, collecting blood specimens of a gastric cancer patient and a healthy control, carrying out high-throughput plasma proteomics detection, and screening out differential expression proteins; and verifying the candidate protein markers by using a prospective queue in the British biological sample library, and finally determining 17 core proteins to obtain the gastric cancer biomarker composition. A gastric cancer risk prediction model is constructed by combining clinical risk factors and protein expression levels of gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the invention can realize accurate layering of gastric cancer risks, decision curve analysis shows that the net benefit of the model is obviously superior to that of a traditional screening method, and an efficient tool is provided for early warning and personalized intervention of gastric cancer.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

The invention discloses a breast milk fat globule membrane protein simulation degree evaluation method based on multi-dimensional similarity weighted fusion, and the method comprises the steps: constructing a breast milk MFGM proteomics database, and obtaining the proteomics data of a to-be-evaluated sample; the method comprises the following steps: obtaining a reference matrix through row screening and column screening based on a breast milk MFGM proteomics database, performing logarithmic transformation on the reference matrix, calculating a mean value and a standard deviation of each feature in the reference matrix, and constructing a Z-score matrix and a missing mask matrix corresponding to the reference matrix; calculating abundance distribution similarity and missing mode similarity of the to-be-evaluated sample; setting a shrinkage coefficient based on the actual overlapping feature number, screening a core protein set according to a set threshold value, and comparing to obtain the missing MFGM protein type of the to-be-detected sample; and constructing a Top-K neighbor center, calculating the feature deviation contribution and abundance difference of the to-be-evaluated sample, and outputting key defect proteins and formula optimization suggestions according to preset feature importance indexes. And the similarity simulation accuracy is improved.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The invention relates to the technical field of biological medicines, in particular to application of panthenol-cytochrome c reductase core protein 2 lactic acid modification as a therapeutic target in preparation of drugs for treating sepsis cardiomyopathy. The invention discloses a key effect of Uqcrc2 K109 site lactic acid modification in SIC and application of the Uqcrc2 K109 site lactic acid modification as a therapeutic target. The Uqcrc2-K109 is found to be a therapeutic target of the SIC through molecular biology methods such as proteomics analysis, lactylation omics analysis and co-immunoprecipitation, and the function of a mitochondrial respiratory chain complex III is recovered in a targeted manner by regulating and controlling the lactylation level of the Uqcrc2-K109, so that a new strategy is provided for treatment of the SIC.

The invention relates to the field of biological detection, in particular to a broad-spectrum specific antibody and application thereof. The invention provides a monoclonal antibody of human immunodeficiency virus P24 protein. Three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 3, 4 and 5; the three CDR regions of the light chain of the gene respectively have amino acid sequences as shown in SEQ ID NO: 7, 8 and 9. A recombinant human immunodeficiency virus P24 protein is used as an immunogen, a monoclonal antibody capable of simultaneously detecting HIV-1 and HIV-2 core proteins P24 is successfully prepared through different multi-type antigen sequential immunization strategies, an epitope interval of the monoclonal antibody is determined through a recombinant P24 fragment, and a foundation is laid for establishing a detection kit with higher sensitivity.

The invention relates to the technical field of organelle separation, and provides a method for rapid purification of peroxisome and oxidation regulation analysis of ultra-long chain fatty acid. The method comprises the following steps: introducing a nucleic acid sequence for coding a fusion protein into a target cell to obtain a cell material, the fusion protein comprising a truncated sequence derived from a peroxisome membrane protein and a tag sequence for affinity purification; taking the cell material as a sample, and separating the peroxisome with the fusion protein from the cell by utilizing an affinity ligand on the basis of a high affinity binding principle. Therefore, according to the method disclosed by the invention, the peroxisome can be rapidly and efficiently enriched, and the whole purification process can be completed within 30 minutes, so that the experimental period is greatly shortened; core protein components of target organelles can be efficiently reserved, and the metabolic activity of peroxisome can be maintained through a complete membrane structure and an internal environment; meanwhile, the same purified sample can synchronously support proteome and metabolome analysis, and direct association of'protein-metabolism 'data is realized.

The invention belongs to the technical field of food processing, and discloses a low-GI protein bar and a preparation method thereof. The low-GI protein bar comprises the following raw materials in parts by mass: 32-48 parts of pretreated egg white liquid, 16-24 parts of whole wheat flour, 8-12 parts of oatmeal, 5.5-8.5 parts of bamboo shoot dietary fibers, 1.5-2.5 parts of chia seeds, 7-11 parts of date palm paste, 4.5-7.5 parts of a sweetening agent and 11-17 parts of auxiliary materials, wherein a preparation method of the pretreated egg white liquid comprises the following steps: adding an acid solution into the egg white liquid to adjust the pH value to 6.5-7, and then carrying out protease enzymolysis treatment. The method effectively solves the problems that a traditional protein bar with egg white as a core protein source is obvious in fishy smell, dry, hard and rough in texture, prone to cracking and scaling in appearance and the like, and the prepared low-GI protein bar is excellent in overall sensory quality and has the nutritional characteristics of being high in protein, high in fiber and low in GI.

The invention relates to the field of molecular biology and medical genetics, and particularly discloses a method for regulating and controlling transport of a TMC1 plasma membrane through TRAPPC3 and application of the method in an auditory function. The TMC1 is a core protein of a hair cell mechanical electrotransduction (MET) channel, and abnormal positioning of the TMC1 is closely related to hereditary hearing loss. The research finds that the transport protein particle compound component TRAPPC3 can specifically interact with the TMC1 protein to promote the TMC1 to be correctly positioned to a cell membrane from cytoplasm, so that the auditory function of hair cells is maintained. According to the method for regulating and controlling the positioning of the TMC1 from the cytoplasm to the cell membrane through co-expression of the TRAPPC3, a functional TMC1 channel can be reconstructed in a heterologous system, and the method is suitable for deafness molecular mechanism research, drug screening and gene therapy strategy development. According to the invention, the TRAPPC3-TMC1 interaction mechanism is provided for the first time, and a new intervention target is provided for hereditary hearing loss treatment.

The application provides a nano-catalytic material system capable of targeting tumors for gene editing, which is obtained by loading a CRISPR / Cas9 plasmid of a gene editing system capable of editing a core protein gene GPX4 related to cell ferroptosis into the pores of an iron single-atom nano-catalyst, and then modifying the cell membrane of a homologous tumor. The nano-catalytic material system provided by the application has excellent Fenton catalytic performance, can accurately edit target genes, induces tumor cells to undergo ferroptosis, and has the advantages of simple synthesis process, low cost, easy batch production, high enrichment degree at a lesion site, good treatment effect, and good clinical application prospect.

The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 μg gB / pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.

The invention belongs to the field of functional food processing, and provides a preparation process of functional soybean milk powder with a sleep improving effect, which adopts a five-step linkage design of germinated soybean enzymolysis, lactobacillus plantarum fermentation, in-situ calcium nucleation, isoelectric point adsorption, exopolysaccharide stabilization and spray drying. Layered coating of the fermentation system autogenous exopolysaccharide and the fermentation modified soybean protein on the organic acid calcium microcrystal core is realized through pH gradient dynamic regulation and control, and a core-protein middle layer-polysaccharide outer layer ternary in-situ composite microcapsule structure is constructed. The multi-target synergy that the gamma-aminobutyric acid is enriched to 150-300 mg / 100 g, the isoflavone aglycone rate reaches 70-85% and the microcapsule D50 is controlled to be 5-80 microns is achieved, the three technical problems that high-solid-content low-viscosity spraying and strong interaction conflict exists, the dry powder flowability and core-shell layer stability conflict exists, and a narrow pH window and amplification tolerance are opposite are solved, and the method has wide functional food application value.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

The invention discloses a microcapsule nutritional feed and a preparation method thereof, and belongs to the technical field of feeds. The microcapsule nutritional feed is prepared from the following raw materials in parts by weight: 20 to 30 parts of corn, 8 to 13 parts of sorghum, 10 to 12 parts of wheat, 5 to 9 parts of soybeans, 2 to 8 parts of fish meal, 0.3 to 0.5 part of glucose, 0.3 to 0.9 part of origanum vulgare essential oil microcapsules, 2 to 4 parts of lysine, 2 to 4 parts of threonine, 2 to 4 parts of methionine, 2 to 4 parts of tryptophan and 0.3 to 0.9 part of vitamin C, the origanum vulgare essential oil microcapsule comprises a core material and a wall material, and the core material is origanum vulgare essential oil; and the wall material is chitosan modified by alpha-lipoic acid and cysteine. The raw material ratio of the microcapsule nutritional feed is scientifically designed around four dimensions of basic energy supply, core protein supplementation, functional microcapsule synergism and nutrition balance and reinforcement, the dosage of each component is highly matched with the function, and the performance of the feed is synergistically improved.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention relates to the field of agricultural antibiosis, in particular to a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof.The composition comprises the long-chain unsaturated fatty acid amide, modified kasugamycin and other effective ingredients, the long-chain unsaturated fatty acid amide is specifically combined with T3SS core protein HrcC, and the modified kasugamycin is specifically combined with T3SS core protein HrcC; the injection body assembly is blocked, and the effect protein secretion is inhibited; kasugamycin can cause that bacteria cannot synthesize necessary functional proteins and die. The two components have a synergistic effect and can exert power at the same time from two aspects of inhibiting bacterial toxicity secretion and basic metabolism, so that the control effect on plant bacterial diseases is effectively improved. In practical application, the composition can greatly reduce damage of diseases to crops, guarantee healthy growth of the crops and improve the yield and quality of the crops, and has a wide application prospect.

The invention discloses an industrial recirculating aquaculture grouper mouth-opening micro-capsule feed and a preparation method thereof, and relates to the technical field of grouper mouth-opening micro-capsule feeds. The feed is composed of 85-90% of a core protein source and 10-15% of a functional additive, and has the characteristics of comprehensive nutrition, good palatability, high stability in water and the like; according to the preparation method, superfine grinding and microencapsulation technologies are adopted, micro-capsule particles are formed through a spray condensation method, low-temperature emulsification and vacuum drying processes are matched, loss of heat-sensitive components is effectively reduced, multi-stage three-dimensional mixing is achieved through an original bevel gear transmission and rotary scraper stirring system, the component mixing uniformity is improved, and the product quality is improved. According to the feed prepared through the technology, the survival rate and the growth speed of juvenile groupers are remarkably increased, the dissolution time of the micro-capsule feed is shortened, energy consumption is reduced, and meanwhile the high efficiency and the environment friendliness are achieved.

The purpose of the present invention is to provide an immunogenic composition containing a new HBV polypeptide or polynucleotides encoding the polypeptide. The immunogenic composition contains at least one polypeptide selected from among polypeptides a) through c) or polynucleotides encoding the polypeptide, and can be used for treating or preventing HBV infection. a) an HBV surface protein polypeptide including a specific amino acid substitution; b) an HBV polymerase polypeptide including an inactivated reverse transcriptase domain and an inactivated ribonuclease H domain, and including a specific amino acid substitution; and c) an HBV core protein polypeptide including a specific amino acid sequence.

The present disclosure provides, in part, 5-membered heteroaryl formamide compounds useful for disrupting HBV core protein assembly and pharmaceutical compositions thereof and methods of treating hepatitis B (HBV) infection.

The application discloses a gastric cancer biomarker composition and a screening method and application thereof, and belongs to the technical field of bioinformatics; the screening method of the gastric cancer biomarker composition comprises the following steps: collecting blood samples of gastric cancer patients and healthy controls, performing high-throughput plasma proteomics detection, and screening out differentially expressed proteins; the candidate protein markers are verified by using a prospective cohort in the UK BioSample Bank, 17 kinds of core proteins are finally determined, and the gastric cancer biomarker composition is obtained; and a gastric cancer risk prediction model is constructed by combining clinical risk factors and the protein expression levels of the gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the application can realize precise stratification of gastric cancer risks, and decision curve analysis shows that the net benefit of the gastric cancer risk prediction model is significantly better than that of a traditional screening method, so that the gastric cancer risk prediction model provides an efficient tool for early warning and personalized intervention of gastric cancer.

The present invention discloses a monoclonal antibody cAbB4 for hepatitis B virus core protein and its preparation and application. cAbB4 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L and CDR3-L of its light chain variable region are SEQ ID NO.4, "SGS" and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening of the present invention has a strong ability to bind to HBc. The present invention verifies the application of cAbB4 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbB4 of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The present invention discloses a monoclonal antibody cAbF9 against hepatitis B virus core protein and its preparation and application. cAbF9 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H, and CDR3-H in its heavy chain variable region are SEQ ID NO.1-3 respectively, and the amino acid sequences of CDR1-L, CDR2-L, and CDR3-L in its light chain variable region are SEQ ID NO.4, "SAS", and SEQ ID NO.5 respectively. The monoclonal antibody screened in the present invention has a strong binding ability to HBc. The present invention verifies the application of cAbF9 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbF9 of the present invention has the characteristics of high efficiency, broad spectrum, and multi-purpose, and has broad application prospects in the field of HBV infection diagnosis.

The invention provides an exosome membrane protein interaction network analysis method, and belongs to the technical field of exosome membrane protein interaction networks. The exosome membrane protein interaction network analysis method provided by the invention comprises the following steps: firstly, obtaining sequence and structure information of a target protein from a database; and then protein attributes are described through the physicochemical feature vectors, and dimensionality reduction clustering is carried out. And evaluating the protein interaction from three dimensions of physicochemical characteristic matching, structural similarity and position correlation by utilizing an innovative protein interaction optimization equation set. After the network is constructed based on the interaction index, topology analysis is carried out by adopting a minimum round-trip path algorithm, and core protein and a regulation function module thereof are finally determined through community division identification function modules, so that high-precision prediction of the exosome membrane protein interaction network is realized. The technical problem of low prediction accuracy of the exosome membrane protein interaction network in the prior art is solved.

Disclosed are: a composition containing a human urine concentrate; a method for producing the same; a cell population; a human urine collection system; a muscle differentiation promoter; and a muscle damage therapeutic agent. The muscle differentiation promoter and the muscle damage therapeutic agent contain a nucleic acid that promotes the expression of serglycin or serglycin core protein.